Rinat (Pfizer Global Research and Development)
230 East Grand Avenue
South San Francisco
About Rinat (Pfizer Global Research and Development)Rinat, located in South San Francisco, CA, is now a part of Pfizer’s Biotherapeutics and Bioinnovation Center (BBC). The center is both independent and interdependent on Pfizer Global Research and Development (PGRD), creating and overseeing a federation of units and collaborations with the academic, biomedical, biotech communities, while collaborating closely with PGRD to discover and develop protein therapeutics that address significant unmet medical needs. At Rinat, we are dedicated to looking at diseases in novel ways to discover new medicines in the quest to design better treatment options for patients suffering from life-threatening and life-altering diseases.
Research at Rinat incorporates the disciplines of protein engineering and biology, and our scientists work closely to bring novel protein-based therapeutics from the bench through to the clinic. By studying the functions and interactions of proteins implicated in human diseases, our protein engineers design drug candidates that are best equipped to fight those diseases, while our biologists use innovative techniques to evaluate the safety and efficacy of the candidates in both in vitro and in vivo studies.
The integration of protein therapeutics into the drug discovery process enables Rinat scientists to potentially both design more successful medicines and significantly reduce the amount of time it takes to bring those new medicines to patients – a process that can take upwards of 10 years.
Rinat was formed in 2001 when Genentech narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. In 2006, Pfizer expanded biotherapeutic research and acquired Rinat.
The Rinat research group offers an exciting challenge for those who are committed to finding new and improved ways to treat diseases – the impact of which has the potential to be felt around the world.
Last Updated: 03-12-2008
3 articles with Rinat (Pfizer Global Research and Development)
8/30/2018Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureT...